Final NHS nod for Janssen’s Imbruvica
February 2, 2018
Source: Pharmatimes
528
Janssen’s Imbruvica will be routinely available on the NHS to treat certain patients with mantle cell lymphoma (MCL), after cost regulators issued a final green light for the drug.
In final guidelines, the National Institute for Health and Care Excellence has approved funding for Imbruvica (ibrutinib) when used to treat the condition in people who have had only one prior line of therapy.
The Institute previously said it could not recommend the drug for the entire MCL patient population as it did not offer the NHS value for money, but that, in the second-line setting, Imbruvica could be considered within ‘end-of-life’ thresholds and its cost effectiveness is likely to be less than £49,848 per QALY gained.
The endorsement is also contingent upon the continued provision of the drug with the confidential discount agreed in the commercial access agreement with NHS England.
Imbruvica is the first in a class of medicines known as Bruton’s tyrosine kinase (BTK) inhibitors, which are designed to specifically block the BTK protein from causing malignant B cells to multiply and spread.
By Ddu
Copyright©2024 Ddu. All rights reserved.
Read more on
- Breakthrough Device Designation Granted to Digital Intervention for Alzheimer’s August 27, 2018
- FDA Approved Eye Drop Oxervate to Treat Neurotrophic Keratitis August 27, 2018
- Experimental Ebola Treatments Approved by Congo as it Sees Flare-Up in Cases August 24, 2018
- First Dual-Lead Nerve Stimulator for Pain Management gets FDA Nod August 22, 2018
- Bristol-Myers Squibb’s Opdivo Ensures a Lung Cancer Position August 22, 2018
your submission has already been received.
OK
Subscribe
Please enter a valid Email address！
Submit
The most relevant industry news & insight will be sent to you every two weeks.
